Table 1

Clinical studies included in the analysis in which subjects received 0.3 mg pegaptanib
Study Duration of Treatment Treatment Groups Pegaptanib sodium 0.3 mg Sham Reference
Subjects
With Diabetes Without Diabetes With Diabetes
N = 165 N = 1421 N = 26
NCT00321997 (EOP1003; randomized) Up to 5 years Pegaptanib 0.3, 1, 3 mg; sham 22 (13.3%) 208 (14.6%) 7 (26.9%) [15]
NCT00021736 (EOP1004; randomized) Up to 5 years Pegaptanib 0.3, 1, 3 mg; sham 20 (12.1%) 182 (12.8%) 14 (53.8%) [17]
NCT00215670 (EOP1006; randomized) Up to 2 years Pegaptanib 0.3, 1, 3 mg 1 (0.6%) 41 (2.9%) 0 (0%) [29]
NCT00087763 (EOP1009; randomized) 1 year; with no treatment weeks 12 to 24 Pegaptanib 0.3, 1 mg; sham 4 (2.4%) 60 (4.2%) 5 (19.2%) *
NCT00088192 (EOP1010; open-label) Up to 3 years Pegaptanib 0.3 mg 67 (40.6%) 370 (26.0%) 0 (0%) [30]
NCT00134667** EOP1012; randomized) Up to 2 years Pegaptanib 0.3 mg; pegaptanib 0.3 mg + PDT 16 (9.7%) 149 (10.5%) 0 (0%)
NCT00150202/ NCT00239928 (A5751010/ A5751015; open-label) Up to 4 years Pegaptanib 0.3, 1 mg 7 (4.2%) 72 (5.1%) 0 (0%) [30]***
NCT00324116 (A5751016; open-label) 1 year Pegaptanib 0.3 mg 11 (6.7%) 70 (4.9%) 0 (0%)
NCT00327470 (A5751017; open-label) Up to 2 years Pegaptanib 0.3 mg 17 (10.3%) 269 (18.9%) 0 (0%)

PDT: photodynamic therapy with verteporfin.

*Unpublished observation ([by author or pharma, year]).

**Unpublished results; trial terminated.

***Study A5751015 was an extension of study A5751010 and were considered as a single study for this manuscript.

Unpublished observations (Estephan M, Troy S, Starita C, for the French Macugen in Early Onset CNV Study Group presented at European Society of Retina Specialists - 10th EURETINA Congress. Paris, France; 2010: Poster 1016).

Dombi et al.

Dombi et al. BMC Ophthalmology 2012 12:37   doi:10.1186/1471-2415-12-37

Open Data